Financials data is unavailable for this security.
View more
Year on year HeiLongJiang ZBD Pharmaceutical Co Ltd had revenues fall -25.50% from 4.22bn to 3.14bn, though the company grew net income 155.00% from 185.39m to 472.74m.
| Gross margin | 64.84% |
|---|---|
| Net profit margin | 23.37% |
| Operating margin | 25.30% |
| Return on assets | 4.10% |
|---|---|
| Return on equity | 6.79% |
| Return on investment | 5.54% |
More ▼
Cash flow in CNYView more
In 2023, HeiLongJiang ZBD Pharmaceutical Co Ltd increased its cash reserves by 47.22%, or 463.87m. Cash Flow from Financing totalled 765.69m or 24.36% of revenues. In addition the company used 478.24m for operations while cash from investing totalled 176.43m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.43 |
|---|---|
| Tangible book value per share | 7.35 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.53 |
|---|---|
| Quick ratio | 2.18 |
| Total debt/total equity | 0.4448 |
|---|---|
| Total debt/total capital | 0.2951 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 614.29% and 155.41%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.85% |
|---|---|
| Div growth rate (5 year) | 4.05% |
| Payout ratio (TTM) | 0.00% |
| EPS growth(5 years) | -1.58 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 80.09 |
More ▼
